BioCentury | Apr 1, 2002
Product Development

Guidant spreading its stent bets

Guidant Corp. 's decision to license Novartis AG 's everolimus anti-proliferative compound for use in drug-eluting stents shouldn't be seen as a vote of no confidence in its Achieve paclitaxol-eluting stents, according to the company....
BC Week In Review | Mar 11, 2002
Clinical News

Actinomycin-D stent: Pilot

Data from the first 90 patients in GDT's pilot ACTION trial showed that the actinomycin-D stent was not effective in preventing restenosis. GDT said that patients treated with the stent had a high target lesion...
BioCentury | Mar 11, 2002

Ebb & Flow

The good news is that biotech almost kept pace with NASDAQ last week; the bad news is it has a ways to go to catch up with the composite on a year-to-date basis. The NASDAQ...
BC Extra | Mar 7, 2002
Clinical News

Guidant halts ACTION

GDT halted ACTION, a clinical trial of actinomycin-D eluting stent, after preliminary results showed that it was not effective in preventing restenosis....
Items per page:
1 - 4 of 4